Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954

Oncogene volume 20, pages 7797–7803 (2001)Cite this article

Abstract

Telomerase activation is considered to be a critical step in cancer progression due to its role in cellular immortalization. The prevalence of telomerase expression in human cancers makes it an attractive candidate for new mechanism-based targets for cancer therapy. The selective killing of cancer cells can be achieved by gene-directed enzyme pro-drug therapy (GDEPT). In this study we have tested the feasibility of using the transcriptional regulatory sequences from the hTERT and hTR genes to regulate expression of the bacterial nitroreductase enzyme in combination with the pro-drug CB1954 in a suicide gene therapy strategy. hTERT and hTR promoter activity was compared in a panel of 10 cell lines and showed a wide distribution in activity; low activity was observed in normal cells and telomerase-negative immortal ALT cell lines, with up to 300-fold higher activity observed in telomerase positive cancer lines. Placing the nitroreductase gene under the control of the telomerase gene promoters sensitized cancer cells in tissue culture to the pro-drug CB1954 and promoter activity was predictive of sensitization to the pro-drug (2–20-fold sensitization), with cell death restricted to lines exhibiting high levels of promoter activity. The in vivo relevance of these data was tested using two xenograft models (C33a and GLC4 cells). Significant tumour reduction was seen with both telomerase promoters and the promoter-specific patterns of sensitization observed in tissue culture were retained in xenograft models. Thus, telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Abdul-Ghani R, Ohana P, Matouk I, Ayesh S, Ayesh B, Laster M, Bibi O, Giladi H, Molnar-Kimber K, Sughayer MA, de Groot N, Hochberg A . 2000 Mol. Ther. 2: 539–544

  • Bailey SM, Hart IR . 1997 Gene Ther. 4: 80–81

  • Bailey SM, Knox RJ, Hobbs SM, Jenkins TC, Mauger AB, Melton RG, Burke PJ, Connors TA, Hart IR . 1996 Gene Ther. 3: 1143–1150

  • Gibbs JB . 2000 Science 287: 1969–1973

  • Greco O, Dachs GU . 2001 J. Cell Physiol. 187: 22–36

  • Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA, Fang B . 2000 Cancer Res. 60: 5359–5364

  • Gunes C, Lichtsteiner S, Vasserot AP, Englert C . 2000 Cancer Res. 60: 2116–2121

  • Harrington KJ, Linardakis E, Vile RG . 2000 Adv. Drug Deliv. Rev. 44: 167–184

  • Heine B, Hummel M, Demel G, Stein H . 1998 J. Pathol. 185: 139–144

  • Hiyama E, Hiyama K, Yokoyama T, Shay JW . 2001 Neoplasia 3: 17–26

  • Hiyama T, Yokozaki H, Kitadai Y, Haruma K, Yasui W, Kajiyama G, Tahara E . 1999 Virchows Arch. 434: 483–487

  • Hoare SF, Bryce LA, Wisman GB, Burns S, Going JJ, van der Zee AG, Keith WN . 2001 Cancer Res. 61: 27–32

  • Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S, Kondo S . 2000 Hum. Gene Ther. 11: 1397–1406

  • Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA, Gerald WL . 1998 Nat. Genet. 19: 182–186

  • Maitra A, Yashima K, Rathi A, Timmons CF, Rogers BB, Shay JW, Gazdar AF . 1999 Cancer 85: 741–749

  • Majumdar AS, Hughes DE, Lichtsteiner SP, Wang Z, Lebkowski JS, Vasserot AP . 2001 Gene Ther. 8: 568–578

  • Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P . 2001 Cancer Res. 61: 749–758

  • Nettelbeck DM, Jerome V, Muller R . 2000 Trends Genet. 16: 174–181

  • Nowak R, Chrapusta SJ . 1998 Cancer Journal From Scientific American 4: 148–154

  • Park TW, Riethdorf S, Riethdorf L, Loning T, Janicke F . 1999 Int. J. Cancer 84: 426–431

  • Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R . 2000 Cancer Res. 60: 6039–6044

  • Sarvesvaran J, Going JJ, Milroy R, Kaye SB, Keith WN . 1999 Carcinogenesis 20: 1649–1651

  • Sharma S, Raymond E, Soda H, Sun D, Hilsenbeck SG, Sharma A, Izbicka E, Windle B, Von Hoff DD . 1997 Ann. Oncol. 8: 1063–1074

  • Shay JW, Zou Y, Hiyama E, Wright WE . 2001 Hum. Mol. Genet. 10: 677–685

  • Soder AI, Going JJ, Kaye SB, Keith WN . 1998 Oncogene 16: 979–983

  • Stanta G, Bonin S, Niccolini B, Raccanelli A, Baralle F . 1999 FEBS Lett. 460: 285–288

  • Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, Inoue M . 1999 Cancer Res. 59: 551–557

  • Urquidi V, Tarin D, Goodison S . 1998 Ann. Med. 30: 419–430

  • Vile RG, Sunassee K, Diaz RM . 1998 Mol. Med. Today 4: 84–92

  • Weedon SJ, Green NK, McNeish IA, Gilligan MG, Mautner V, Wrighton CJ, Mountain A, Young LS, Kerr DJ, Searle PF . 2000 Int. J. Cancer 86: 848–854

  • Weng N, Levine BL, June CH, Hodes RJ . 1997 J. Immunol. 158: 3215–3220

  • White LK, Wright WE, Shay JW . 2001 Trends Biotechnol. 19: 114–120

  • Wisman GB, De Jong S, Meersma GJ, Helder MN, Hollema H, De Vries EG, Keith WN, Van Der Zee AG . 2000 Hum. Pathol. 31: 1304–1312

  • Yashima K, Maitra A, Rogers BB, Timmons CF, Rathi A, Pinar H, Wright WE, Shay JW, Gazdar AF . 1998 Cell Growth Diff. 9: 805–813

  • Yi X, Tesmer VM, Savre-Train I, Shay JW, Wright WE . 1999 Mol. Cell. Biol. 19: 3989–3997

  • Zhao JQ, Glasspool RM, Hoare SF, Bilsland A, Szatmari II, Keith WN . 2000 Neoplasia 2: 531–539

  • Zhao JQ, Hoare SF, McFarlane R, Muir S, Parkinson EK, Black DM, Keith WN . 1998 Oncogene 16: 1345–1350

Download references

Acknowledgements

This work was supported by the Cancer Research Campaign (UK) and Glasgow University. We would like to thank Dr Caroline Springer for an initial gift of CB1954.

Author information

Authors and Affiliations

  1. CRC Department of Medical Oncology, University of Glasgow, CRC Beatson Laboratories, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD, UK

    Jane A Plumb, Alan Bilsland, Rania Kakani, Jiangqin Zhao, Rosalind M Glasspool, T R Jeffry Evans & W Nicol Keith

  2. Enact Pharma Plc, Porton Down Science Park, Salisbury, SP4 0JQ, UK

    Richard J Knox

Authors
  1. Jane A Plumb
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan Bilsland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rania Kakani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiangqin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rosalind M Glasspool
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Richard J Knox
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T R Jeffry Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W Nicol Keith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W Nicol Keith.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Plumb, J., Bilsland, A., Kakani, R. et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 20, 7797–7803 (2001). https://doi.org/10.1038/sj.onc.1204954

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204954

Keywords

This article is cited by

Search

Advanced search

Quick links